Paydirt
KF
Insider

Kevin Joseph Fitzgerald

CSO & EVP, Head of Research

Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Alnylam Pharmaceuticals, Inc. (ALNY). The largest single filing was $5.4M of ALNY (11,903 sh across 9 lots, as filed), executed Nov 17 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
5
0 buys · 5 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$8.7M
shares × price, as filed
Last traded
Mar 3
Filed Mar 4

Median ADV $470.9M across their filed names

Open performance
Volume by month
$5.4M$2.7M$0Oct 2024Apr 2025Oct 2025Apr 2026Nov 2024 · sells $422KFeb 2025 · sells $272KMar 2025 · sells $232KAug 2025 · sells $505KOct 2025 · sells $702KNov 2025 · sells $5.4MJan 2026 · sells $730KFeb 2026 · sells $1.3MMar 2026 · sells $583K
Buys $0 Sells $10.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names
ALNY Alnylam Pharmaceuticals, Inc. ALNY · 0 buys · 9 sells 9 filings
Recent filings
ALNYSALE Alnylam Pharmaceuticals, Inc. View filing → $422K
1,677 sh across 2 lots
Exec Nov 26 2024
Filed Nov 27 2024 · 5:30 PM ET